Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Inclusion criteria:

diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT

Inclusion Criteria:

• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• Potentially Resectable NSCLC
• Treatment Plan is Crizotinb or Standard Chemotherapy

Exclusion Criteria:

• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women